Paclitaxel Encapsulated in Cationic Liposomes Diminishes Tumor Angiogenesis and Melanoma Growth in a “Humanized” SCID Mouse Model

Arap, 1998, Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model, Science, 279, 377, 10.1126/science.279.5349.377 Belotti, 1996, The microtubule-affecting drug paclitaxel has antiangiogenic activity, Clin Cancer Res, 2, 1843 Brien, 1989, Rapid in situ cellular kinetics of intracerebral tumor angiogenesis using a monoclonal antibody to bromodeoxyuridine, Neusosurgery, 25, 715, 10.1227/00006123-198911000-00005 Browder, 2000, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer, Cancer Res, 60, 1878 Cabanes, 1998, Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel, Int J Oncol, 12, 1035 Carmeliet, 2000, Angiogenesis in cancer and other diseases, Nature, 407, 249, 10.1038/35025220 Chang, 1997, Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer, Semin Oncol, 24, S17 Ellerby, 1999, Anti-cancer activity of targeted pro-apoptotic peptides, Nat Med, 5, 1032, 10.1038/12469 Featherstone, 2002, From the analyst's coach: drugs that target angiogenesis, Nature Rev Drug Discovery, 1, 413, 10.1038/nrd824 Folkman, 1971, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108 Forastiere, 2001, Phase III comparison of high-dose paclitaxel+cisplatin+granulocyte colony-stimulating factor versus low-dose paclitaxel+cisplatin in advanced head and neck cancer: Eastern cooperative oncology group study e1393, J Clin Oncol, 19, 1088, 10.1200/JCO.2001.19.4.1088 Gasparini, 2001, Metronomic scheduling. The future of chemotherapy?, Lancet Oncol, 2, 733, 10.1016/S1470-2045(01)00587-3 Gröger, 1999, Immune complexes from vasculitis patients bind to endothelial Fc receptors independent of the allelic polymorphism of FcgammaRIIa, J Invest Dermatol, 113, 56, 10.1046/j.1523-1747.1999.00620.x Harigai, 2001, Preferential binding of polyethylene glycol-coated liposomes containing a novel cationic lipid, TRX-20, to human subendothelial cells via chondroitin sulfate, Pharm Res, 18, 1284, 10.1023/A:1013033826974 Hashizume, 1997, Openings between defective endothelial cells explain tumor vessel leakiness, Am J Pathol, 156, 1363, 10.1016/S0002-9440(10)65006-7 Hu, 2001, Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer, Proc Natl Acad Sci USA, 98, 12180, 10.1073/pnas.201420298 Klement, 2000, Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity, J Clin Invest, 105, R15, 10.1172/JCI8829 Kunstfeld, 1997, HECA-452+ T cells migrate through superficial vascular plexus but not through deep vascular plexus endothelium, J Invest Dermatol, 108, 343, 10.1111/1523-1747.ep12286483 Lau, 1999, Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer, Cancer Biother Radiopharm, 14, 31, 10.1089/cbr.1999.14.31 Ling, 2001, Disruption of cell adhesion and caspase-mediated proteolysis of β-and γ-catenins and APC protein in paclitaxel-induced apoptosis, Mol Pharmacol, 59, 593, 10.1124/mol.59.3.593 Liu, 1997, Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery, Nat Biotechnol, 15, 167, 10.1038/nbt0297-167 McLean, 1997, Organ-specific endothelial cell uptake of cationic liposome–DNA complexes in mice, Am J Physiol, 273, H387 Nabholtz, 1996, Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer, J Clin Oncol, 14, 1858, 10.1200/JCO.1996.14.6.1858 Nilsson, 2001, Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice, Cancer Res, 61, 711 Norman, 2000, Hypoxia promotes fibrogenesis in human renal fibroblasts, Kidney Int, 58, 2351, 10.1046/j.1523-1755.2000.00419.x Oku, 2000, Evaluation of drug targeting strategies and liposomal trafficking, Curr Pharm Des, 6, 1669, 10.2174/1381612003398816 O'Reilly, 1998, Endostatin: an endogenous inhibitor of angiogenesis and tumor growth, Cell, 88, 277, 10.1016/S0092-8674(00)81848-6 Petzelbauer, 1993, Heterogeneity of dermal microvascular endothelial cell antigen expression and cytokine responsiveness in situ and in cell culture, J Immunol, 151, 5062 Petzelbauer, 1996, Human delayed-type hypersensitivity reaction in a SCID mouse engrafted with human T cells and autologous skin, J Invest Dermatol, 107, 576, 10.1111/1523-1747.ep12582823 Ramesh, 2001, Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector, Mol Ther, 3, 337, 10.1006/mthe.2001.0266 Rathmann, 1999, Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer: preliminary results, Semin Radiat Oncol, 9, 130 Sharma, 1996, Novel TaxolR formulation: polyvinylpyrrolidone nanoparticle-encapsulated TaxolR for drug delivery in cancer therapy, Oncol Res, 8, 281 Sugano, 2000, Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice, Cancer Res, 60, 6942 Tajima, 2001, Hypoxic enhancement of type IV collagen secretion accelerates adipose conversion of 3T3-L1 fibroblasts, Biochem Biophys Acta Mol Cell Res, 1540, 179, 10.1016/S0167-4889(01)00114-8 Thurston, 1998, Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice, J Clin Invest, 101, 1401, 10.1172/JCI965 Zhou, 2002, Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model, Cancer Res, 62, 2561